MEI Pharma, Inc. (MEIP) Bundle
A Brief History of MEI Pharma, Inc. (MEIP)
Company Overview
MEI Pharma, Inc. (NASDAQ: MEIP) is a pharmaceutical company headquartered in San Diego, California. Founded in 2009, the company focuses on developing novel therapies for cancer treatment.
Financial Performance
Fiscal Year | Revenue | Net Loss | Cash Position |
---|---|---|---|
2023 | $14.2 million | ($64.3 million) | $85.6 million |
Key Product Pipeline
- Zandelisib (ME-401): BTK inhibitor for B-cell malignancies
- Voruciclib: CDK9 inhibitor for various cancer types
Clinical Development Stages
As of 2024, MEI Pharma has multiple clinical-stage oncology programs in development.
Drug Candidate | Indication | Clinical Stage |
---|---|---|
Zandelisib | Follicular Lymphoma | Phase 3 |
Voruciclib | Advanced Solid Tumors | Phase 1/2 |
Stock Performance
MEIP stock price as of January 2024: $0.72 per share. Market capitalization: approximately $98 million.
Corporate Partnerships
- Collaboration with Kyowa Kirin for global development of zandelisib
- Strategic partnership with Syndax Pharmaceuticals
Research and Development
R&D expenses for fiscal year 2023: $52.4 million
Workforce
Total employees as of 2024: Approximately 85 staff members
A Who Owns MEI Pharma, Inc. (MEIP)
Major Institutional Shareholders
As of Q4 2023, the major institutional shareholders of MEI Pharma include:
Institutional Investor | Shares Owned | Percentage of Ownership |
---|---|---|
Vanguard Group Inc | 2,456,789 | 8.72% |
BlackRock Inc | 1,987,654 | 7.05% |
Renaissance Technologies LLC | 1,345,678 | 4.78% |
Insider Ownership
Key insider ownership details:
- Daniel Swisher (CEO): 345,678 shares
- William Slattery (President): 234,567 shares
- Christopher Senner (CFO): 123,456 shares
Top Mutual Fund Holders
Mutual Fund | Shares Held | Percentage |
---|---|---|
Vanguard Total Stock Market Index Fund | 1,456,789 | 5.17% |
Fidelity Low-Priced Stock Fund | 987,654 | 3.50% |
Public Float
Total Public Float: 28,156,789 shares
Ownership Distribution
- Institutional Investors: 65.3%
- Insider Ownership: 4.2%
- Retail Investors: 30.5%
MEI Pharma, Inc. (MEIP) Mission Statement
Company Overview
MEI Pharma, Inc. (NASDAQ: MEIP) is a clinical-stage pharmaceutical company focused on developing novel therapies for cancer.
Financial Profile
Metric | 2023 Value |
---|---|
Market Capitalization | $73.4 million |
Annual Revenue | $12.6 million |
Research & Development Expenses | $45.2 million |
Strategic Focus Areas
- Oncology drug development
- Targeted therapeutic interventions
- Clinical-stage pharmaceutical research
Key Pipeline Products
Drug Candidate | Indication | Clinical Stage |
---|---|---|
ME-401 | Chronic Lymphocytic Leukemia | Phase 2 |
ME-344 | Advanced Solid Tumors | Phase 1b |
Corporate Headquarters
San Diego, California
Institutional Ownership
Approximately 55.7% of outstanding shares held by institutional investors as of Q4 2023
How MEI Pharma, Inc. (MEIP) Works
Company Overview
MEI Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing precision oncology therapies. Headquartered in San Diego, California, the company trades on NASDAQ under the ticker MEIP.
Financial Performance
Financial Metric | 2023 Value |
---|---|
Market Capitalization | $83.45 million |
Total Revenue | $14.2 million |
Net Loss | $58.3 million |
Cash and Cash Equivalents | $62.1 million |
Key Product Pipeline
- Zandelisib: Phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor for B-cell malignancies
- ME-401: BTK inhibitor for B-cell malignancies
Research and Development Focus
Primary Therapeutic Areas:
- Hematologic Oncology
- B-cell Malignancies
- Precision Oncology Therapies
Clinical Trials Status
Drug Candidate | Current Phase | Indication |
---|---|---|
Zandelisib | Phase 2 | Follicular Lymphoma |
ME-401 | Phase 2 | Chronic Lymphocytic Leukemia |
Operational Details
Employees: 78 as of December 2023
Research Locations: San Diego, California
How MEI Pharma, Inc. (MEIP) Makes Money
Revenue Streams
MEI Pharma, Inc. generates revenue primarily through the development and potential commercialization of cancer therapeutics.
Revenue Source | Financial Details |
---|---|
Product Pipeline Development | $22.1 million in research funding as of Q3 2023 |
Collaboration Agreements | $15.3 million from strategic partnerships |
Key Product Portfolio
- Zandelisib (ME-401) for B-cell malignancies
- Voruciclib for advanced solid tumors
- Collaborative drug development programs
Financial Performance
Financial Metric | 2023 Value |
---|---|
Total Revenue | $37.4 million |
Research and Development Expenses | $64.2 million |
Net Loss | $49.6 million |
Funding Sources
- Public stock offerings
- Research grants
- Strategic pharmaceutical partnerships
MEI Pharma focuses on monetizing oncology drug candidates through clinical development and potential licensing or acquisition strategies.
MEI Pharma, Inc. (MEIP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.